利索-全球专利检索

  1. 登录
  2. 注册
发明授权
US08021860B2 Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes 有权
通过人淋巴细胞的定点体外免疫产生人自身抗体的方法

  • 专利标题： Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes
  • 专利标题（中）： 通过人淋巴细胞的定点体外免疫产生人自身抗体的方法
  • 申请号： US12318679
    申请日： 2009-01-06
  • 公开(公告)号： US08021860B2
    公开(公告)日： 2011-09-20
  • 发明人: Li-Te Chin , Shu-Ching Hsu
  • 申请人： Li-Te Chin , Shu-Ching Hsu
  • 代理机构： Bacon & Thomas, PLLC
  • 主分类号： C12P21/04
  • IPC分类号： C12P21/04
Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes
摘要：
A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
摘要（中）：

公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。

公开/授权文献
信息查询
Espacenet
0/0